Dapagliflozin Therapy In Cardiac Surgery

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 178 participants.

Also called NCT05621551

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 178 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05621551
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05621551. Randomized; single masking; primary purpose treatment. Start 2022-11-11 (actual); primary completion 2024-06-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin Therapy In Cardiac Surgery
Condition
Diabetes Mellitus, Type 2
Condition
Cardiac Surgery
Intervention (Drug)
Dapagliflozin
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct05621551
Content hash
deb26f6ec2e09b4bb59a3f9d31a08e68d9d133ecb275bc039c3be5ad87f32e0c